German Drug and Addiction Commissioner Backs Nicotine Pouch Ban, Calls for Stricter Regulation

Nov.22.2024
German Drug and Addiction Commissioner Backs Nicotine Pouch Ban, Calls for Stricter Regulation
Germany's Federal Drug and Addiction Commissioner has called for stricter enforcement of the nicotine pouch ban, highlighting shortcomings in the current implementation of youth protection regulations.

According to GMX on November 22, German Federal Drug and Addiction Commissioner Burkhard Blienert is pushing for a ban on nicotine pouches.

 

The commissioner stated in an interview with the German news agency: "Nicotine pouches are neither healthy nor safe. People can ingest large amounts of nicotine in a short period of time through them, and the product is highly addictive."

 

He believes that solely relying on youth protection laws is impractical, which has been validated in the current situation of disposable vapes.

 

Addiction counselors pointed out that nicotine pouches are becoming increasingly popular among students. Despite the products being banned from sale, they can still be purchased online. Prevention organizations criticized the lack of enforcement of the ban.

 

The coordinator of the Lower Saxony Addiction Office, Ricarda Henze, said, "The enforcement of laws protecting teenagers must be strictly monitored, and strict punishments should be imposed for violations."

 

Burkhard Blienert is the Commissioner for Drug and Addiction Policy of the Federal Government in Germany, and has been serving as the Federal Commissioner for Drugs in the Federal Ministry of Health under Chancellor Olaf Scholz's government since 2022.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE® Nicotine Pouches announced a partnership with Taylor Reimer Racing, becoming the Official Nicotine Sponsor for four races in the 2026 ARCA Menards Series and serving as the primary sponsor at events in Alabama, Michigan, Minnesota, and Arizona. FRE branding will appear on the race car, driver suit, and helmet, and the collaboration will also extend to off-track content and activations.
Feb.27
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
British American Tobacco reported FY2025 revenue of £25.61 billion, down 1.0% on a reported basis but up 2.1% at constant currency. New Categories revenue rose 5.5%, with category contribution increasing 77%. Smokeless products accounted for 18.2% of group revenue.
Feb.12
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan will enforce a total ban on the circulation of electronic nicotine delivery systems from March 1, covering legal sales, storage and imports. Consumers are offered a legal option to avoid criminal liability by voluntarily handing prohibited devices to law enforcement. The report says imports had already effectively stalled in early 2025, leaving sellers to clear remaining stock.
Feb.27 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
RLX Technology 2025 Revenue Rises 44.0% YoY to Nearly USD 566.1 million, International Business Accounts for 76.5% in Q4
RLX Technology 2025 Revenue Rises 44.0% YoY to Nearly USD 566.1 million, International Business Accounts for 76.5% in Q4
RLX Technology Inc. announced its unaudited financial results for the fourth quarter and full year of 2025. Q4 net revenue reached RMB 1.1413 billion, a 40.3% year-over-year increase, while full-year net revenue grew 44.0% to RMB 3.9589 billion.
Mar.13 by 2FIRSTS.ai